Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALANCE: Salvage Radiotherapy With or Without Apalutamide in Recurrent Prostate Cancer
NCT03371719Phase 2Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Jun 2018
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of apalutamide in prostate cancer (PCa), sponsored by NRG Oncology. Started Jun 2018; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03371719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03371719.